贝伐单抗治疗结直肠癌的耐药机制研究进展  

Research Progress of Bevacizumab's Resistance Mechanisms in the Treatment of Colorectal Cancer

作　　者：刘星洲 涂水平[1] 

机构地区：[1]上海交通大学医学院附属仁济医院肿瘤科,上海200127

出　　处：《医学综述》2017年第15期2972-2977,共6页Medical Recapitulate

摘　　要：肿瘤的生长、侵袭和浸润与肿瘤血管生成有密切联系,目前已知血管内皮生长因子(VEGF)在肿瘤血管生成中发挥重要作用。2010年,以VEGF为靶点的重组人源化单克隆抗体——贝伐单抗在中国上市。作为抗血管生成药物,其主要用于结直肠癌、乳腺癌、非小细胞肺癌等实体瘤的治疗。贝伐单抗虽然在临床上取得了较好的疗效,但仍无法避免耐药问题。其耐药机制尚未阐明,可能与肿瘤微环境、旁路血管生成通路激活及免疫抑制有关。未来,关于贝伐单抗耐药机制的研究将有助于开发更有效的抗血管生成药物。The relationship between angiogenesis and tumors growth or invasion is close. Vascular endothelial growth factor（VEGF） plays a critical role by promoting new vessel. Bevacizumab is a monoclonal antibody that binds VEGF and it is approved for an anti-angiogenic drug in 2010 in China. Now bevacizumab is mainly used in the treatment of metastatic colorectal cancer, metastatic breast cancer and non-smaU cell lung carcinoma. Bevacizumab has great effects in clinical, but an unsolved problem with bevacizumab is drug resistance. The mechanism of drug resistance has not been elucidated, which may be related to tumor microenvironment, bypass angiogenesis, activation of pathway and immunosuppression. Future research into the mechanisms of bevacizumab resistance will help to develop more effective anti-angiogenic drugs.

关 键 词：结直肠癌 肿瘤血管生成 贝伐单抗 耐药机制 

分 类 号：R735.3[医药卫生—肿瘤]